Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

NIH Awards $43 Million to Washington University to Expand Inherited Alzheimer Network Cohort

The NIH awarded $43 million to Washington University School of Medicine to double enrollment in the Dominantly Inherited Alzheimer Network cohort.

Medically reviewed byDr. Diana Nieves Castro, MD
Published 21 Nov 2026· Last updated 21 Nov 2026· 6 minute read
A magnetic resonance imaging scanner used for medical neuroimaging research
Photo: Walter Davies / Wikimedia Commons, CC BY-SA 4.0 (cropped). Source · Licence

The National Institute on Aging at the National Institutes of Health has awarded a five-year, $43 million grant renewal to Washington University School of Medicine in St. Louis to double enrollment in the Dominantly Inherited Alzheimer Network Observational Study. Announced on November 19, 2026, the expansion scales international tracking of autosomal dominant mutation carriers, generating critical biomarker datasets for institutional trial units and regulatory natural history comparisons.

Federal Grant Award and Network Expansion

The National Institute on Aging (NIA), a division of the U.S. National Institutes of Health (NIH), has awarded $43 million over five years to Washington University School of Medicine in St. Louis (WashU Medicine) to fund the next phase of the Dominantly Inherited Alzheimer Network Observational Study (DIAN Obs). The award finances an expansion of the global research network, enabling investigators to double participant enrollment from over 750 participants to approximately 1,500 individuals across clinical sites in the United States and 10 countries.

DIAN Obs investigates families affected by autosomal dominant Alzheimer’s disease (ADAD), a rare, early-onset form caused by deterministic mutations in the APP, PSEN1, or PSEN2 genes. Because each child of a carrier has a 50% chance of inheriting the mutation, nearly all carriers develop dementia at predictable ages, typically in their 30s, 40s, or 50s. The study tracks mutation carriers alongside non-carrier siblings, transforming familial predictability into a clear timeline of neurodegeneration decades before memory loss begins, as documented in biomedical reporting by News-Medical.

“Because these families can tell us roughly when symptoms are likely to start, we can map how the disease unfolds 20 or more years before memory fails,” said Eric McDade, DO, professor of neurology at WashU Medicine and director of DIAN. “And because the biology looks remarkably similar to the far more common late-onset form of Alzheimer’s that emerges in older ages, what we learn here can help everyone at risk.”

Study Architecture, Biomarker Protocols, and Grant Scope

Under the five-year renewal, DIAN Obs will conduct harmonized cognitive testing, neuroimaging, and biofluid collection across participating academic medical centers. As detailed in analysis by Laboes, these multi-modal evaluations establish temporal trajectories of disease pathology across pre-symptomatic and symptomatic phases.

Parameter Prior Consortium Baseline Expanded Scope (2026–2031 Award)
Cohort Enrollment Over 750 participants enrolled since 2008 Targeting approximately 1,500 participants
Participating Sites Sites across the U.S. and 10 countries Addition of newly established Latin American sites
Pre-Symptomatic Ratio Roughly 75% asymptomatic at entry Continued tracking up to 25 years before expected onset
Biomarker Assays CSF amyloid/tau, structural MRI, amyloid PET High-sensitivity plasma p-tau217, longitudinal tau PET
Resilience Analysis Standard observational tracking Multi-omic profiling of delayed-onset gene carriers
Treatment Monitoring Post-trial registry observation Tracking patients on amyloid immunotherapy over 10 years

According to standardized observational testing protocols, about three-quarters of enrolled volunteers had no symptoms at study entry. This cohort structure provides scientists with rare visibility into early biological alterations prior to clinical impairment.

Scientific Background and Evolution of Longitudinal Biomarkers

DIAN Obs was launched at WashU Medicine in 2008 by Dr. John C. Morris, MD, the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology. Because late-onset Alzheimer’s develops insidiously over decades, Morris established DIAN to evaluate deterministic monogenic families whose parental histories reveal expected years to symptom onset. This design enabled researchers to sequence pathological changes with chronological precision, reflecting principles observed in broader longitudinal aging studies.

Over eighteen years, DIAN revealed that cerebrospinal fluid amyloid declines approximately 25 years before symptom onset, followed by positive amyloid PET scans at 15 to 20 years, increased tau levels at 10 to 15 years, and measurable cognitive changes within 5 years of diagnosis. In 2012, WashU Medicine established the Knight Family DIAN Trials Unit (DIAN-TU), led by Dr. Randall J. Bateman, MD, to evaluate preventive therapies. Documented in the Knight Family DIAN Trials Unit registry (NCT01760005), DIAN Obs serves as the external natural-history comparator for DIAN-TU, illustrating how master protocol and platform trial frameworks optimize rare-disease clinical trials.

Consortium Leadership and Participant Perspectives

The renewed award funds critical scientific priorities led by consortium researchers. Dr. Jorge J. Llibre-Guerra, MD, associate professor of neurology at WashU Medicine and associate director of DIAN, leads an initiative expanding sites into Latin America to increase cohort genetic diversity and clinical trial access.

Investigators will also analyze individuals who inherited deterministic mutations but resisted cognitive symptoms well past their expected onset age, utilizing genomic sequencing to identify protective biological factors. Additionally, the team will monitor participants treated with amyloid immunotherapies for over a decade to assess disease progression after plaque clearance.

Marty Reiswig, 48, a study participant from Denver who lost three generations of family to early-onset Alzheimer’s, serves on the DIAN steering committee. “Five more years of funding is massive,” Reiswig said. “It is foundational. What a boon for people in my shoes who are looking for hope and want to be part of good science. My hope is that Alzheimer’s will go the way of heart disease or high blood pressure, where you get your labs done, and if you are on that path, you get a drug, hopefully as simple as a pill. I do not think that is pie in the sky anymore.”

Implications for Academic Medical Centers and Research Offices

For university research administration offices, the grant renewal exemplifies regulatory complexities in multi-site international research supported by federal cooperative agreements and multi-year grants.

Consortium programs operating across global sites require single IRB (sIRB) oversight under the Revised Common Rule, alongside cross-border ethical authorizations and genetic disclosure protocols. Data governance frameworks must reconcile NIH data sharing policies with international privacy regulations, including the European Union’s GDPR and Latin American data laws, while securing protected health information and sensitive participant data under HIPAA.

Additionally, sponsored program teams must administer multi-currency international subawards, material transfer agreements for biospecimens, and standardized laboratory cold-chain monitoring across diverse legal jurisdictions.

Operational Milestones and Longitudinal Study Timeline

Throughout the 2026–2031 cycle, WashU Medicine and international partner sites will execute phased milestones. Initial activities focus on activating five newly credentialed clinical sites across Latin America and deploying validated bilingual cognitive protocols.

The consortium biomarker core will integrate high-throughput plasma p-tau217 assays for remote pre-screening, while DIAN-TU advances ongoing primary prevention trials treating individuals up to 25 years before expected symptom onset. Periodic open-access data releases will continue through the National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) to support external research collaborations.

Sources

Ask CASRAI · full access

Ask about this story

Full access: large monthly usage, up to 10 source passages behind each answer, and MCP and API access for Claude Code, Codex and other CLIs. Cancel any time.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →